Quick Answer
Amla Cardiometabolic Meta-Analysis has evidence relevant to safety, limits, and clinician-discussion contexts, but conclusions should stay close to the cited sources. One representative finding is: Dysregulation of this axis contributes to hypercholesterolemia and cardiometabolic risk, beyond classical cholesterol synthesis pathways.
Key Takeaways
- 01Dysregulation of this axis contributes to hypercholesterolemia and cardiometabolic risk, beyond classical cholesterol synthesis pathways. [Uberti F (2026)]
- 02In HepG2 cells, MIX demonstrated synergistic effects: it reduced HMGR expression by 83-90% relative to individual extracts, increased LDLR expression by 43-97%, suppressed PCSK9 by up to 92%, and lowered total cholesterol and LDL uptake more effectively than RYRF. [Uberti F (2026)]
- 03MIX also amplified bile acid production and free cholesterol excretion, indicating improved hepatic clearance pathways. [Uberti F (2026)]
- 04Background/Objectives: The gut-liver axis plays a central role in cholesterol homeostasis, linking intestinal absorption, microbial metabolites, and hepatic lipid regulation. [Uberti F (2026)]
The current Migaku evidence database contains 1 reusable source document for Amla Cardiometabolic Meta-Analysis. This answer focuses on safety, limits, and clinician-discussion contexts.
- Dysregulation of this axis contributes to hypercholesterolemia and cardiometabolic risk, beyond classical cholesterol synthesis pathways. [Uberti F (2026); evidence level 4]
- In HepG2 cells, MIX demonstrated synergistic effects: it reduced HMGR expression by 83-90% relative to individual extracts, increased LDLR expression by 43-97%, suppressed PCSK9 by up to 92%, and lowered total cholesterol and LDL uptake more effectively than RYRF. [Uberti F (2026); evidence level 4]
- MIX also amplified bile acid production and free cholesterol excretion, indicating improved hepatic clearance pathways. [Uberti F (2026); evidence level 4]
- Background/Objectives: The gut-liver axis plays a central role in cholesterol homeostasis, linking intestinal absorption, microbial metabolites, and hepatic lipid regulation. [Uberti F (2026); evidence level 4]
Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording.
This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.
Sources